4.7 Review

Gender issues in antiepileptic drug treatment

期刊

NEUROBIOLOGY OF DISEASE
卷 72, 期 -, 页码 217-223

出版社

ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.nbd.2014.05.011

关键词

Epilepsy; Antiepileptic drugs; Gender; Pharmacokinetics; Pregnancy; Menopause

资金

  1. European Union
  2. Italian Medicines Agency
  3. Italian Ministry of Health
  4. Italian Ministry for Education, University and Research
  5. C. Mondino National Neurological Institute
  6. Eisai
  7. GSK
  8. Medichem
  9. Sun Pharma
  10. Supernus
  11. UCB Pharma
  12. Vertex
  13. Viropharma
  14. Stockholm County Council
  15. AFA Insurance
  16. CURE
  17. UCB
  18. Sanofi-Aventis
  19. Novartis
  20. Bial

向作者/读者索取更多资源

The purpose of this review is to discuss gender-related aspects in the, pharmacokinetics, effects, selection and use of antiepileptic drugs (AED). In general, there are few known gender related differences in pharmacokinetics or efficacy of AEDs. Conversely, gender has a significant influence on the susceptibility to certain adverse effects, not the least those involving alterations in sex hormone metabolism. Particularly relevant are the teratogenic effects of AEDs, with important differences among AEDs in their potential to cause adverse effects on the fetus when used during pregnancy. Pregnancy can also markedly affect the pharmacokinetics of several AEDs, and dose adjustments are often needed during pregnancy to maintain seizure control. Some treatments that are used only by women, such as contraceptive steroids and hormone replacement therapy, can also interact with AEDs to an extent that may affect the utilization of both the AEDs and the other drug. (C) 2014 Published by Elsevier Inc.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据